Resmed Inc. (ASX:RMD): FY27 First-Quarter Results and Sleep Health Operations

Aditi Sarkar

02 November 2026 06:10 PM AEDT

Resmed Inc. (ASX:RMD): FY27 First-Quarter Results and Sleep Health Operations

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Resmed Inc. (ASX:RMD) closed at AUD 33.38 on 2 November 2026.
Official company disclosures describe its 2026 operating and financial position.
Recent updates identify key operating or product developments.
Further financial and operational reporting remains relevant.

Resmed Inc. (ASX:RMD) supplies sleep and breathing health devices, masks and associated software services internationally. Its Business includes equipment used in managing sleep-disordered breathing and digital support for healthcare providers. Resmed shares closed at AUD 33.38 on 2 November 2026, following publication of its first-quarter FY2027 results.

Company Business and Operating Model

The company operates in sleep and breathing health across the Americas and other international markets. Device and mask sales are accompanied by residential-care software activities. The operating segments have different Revenue drivers, including equipment replacement, patient access, reimbursement, provider Demand and software subscriptions.

Recent 2026 Developments

On 29 October 2026, Resmed announced revenue of USD 1.415 billion for the three months ended 30 September 2026, an increase of 6% from USD 1.336 billion in the comparable quarter. Its reported growth was 7% on the company’s core constant-currency basis. The distinction matters because currency adjustments and the reported consolidated totals use different calculation conventions.

Resmed reported GAAP Net Income of USD 418 million, compared with USD 349 million a year earlier, and Diluted Earnings per Share of USD 2.92, up 23%. Non-GAAP diluted earnings per share were USD 2.91, up 14%. GAAP and management-adjusted figures should not be used interchangeably when assessing profitability.

Financial Performance and Sector Context

The GAAP gross Margin was 61.5%, compared with 61.2% in the prior-year quarter. Operating Income was USD 453 million, up from USD 447 million, while the GAAP Operating Margin declined to 32.0% from 33.4%. Thus a rise in net income occurred alongside a narrower operating margin, illustrating why individual earnings measures Warrant separate examination.

Operating cash flow was USD 422 million, down from USD 457 million. Free cash flow, as defined by the company, was USD 374 million, compared with USD 414 million. These movements provide context for cash conversion and Investment spending rather than a definitive conclusion about subsequent quarters.

Resmed reaffirmed FY2027 guidance for reported revenue of USD 5.75 billion to USD 5.85 billion and core constant-currency growth of 5% to 7%. It also reiterated non-GAAP diluted earnings-per-share guidance of USD 12.00 to USD 12.25. Guidance describes management expectations and is not the same as achieved results.

Risks to Consider

The company disclosed a quarterly Cash Dividend of USD 0.66 per US-listed common share, with a November Record Date and December payment. Australian CDI holders receive a currency-equivalent amount reflecting the CDI ratio. This Capital return is one part of the company’s financial disclosures rather than the central measure of operating performance.

Revenue growth, net profit and cash flow measure different aspects of operating performance. The increase in quarterly net income does not negate the reported decline in operating cash flow, just as higher device sales do not necessarily imply equivalent movement in software revenue. The segment and margin disclosures are therefore useful for understanding how operating performance translates into earnings and available cash.

What to Watch Next

Resmed Inc. (ASX:RMD) remains exposed to reimbursement settings, healthcare equipment demand, competition, exchange rates and Supply arrangements. Research and Development spending increased to USD 103 million from USD 89 million in the quarter. Changes in operating costs and product mix can affect margins even when consolidated sales increase.

Key Insights

Subsequent results will clarify whether revenue remains within the FY2027 guidance range and how operating margin and cash generation develop. Resmed Inc. (ASX:RMD) has disclosed both statutory and adjusted performance measures, providing a basis for monitoring its sleep-health business without assuming future outcomes.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.